Biomind Labs Inc. (BMNDF)
BMNDF Stock Price Chart
Explore Biomind Labs Inc. interactive price chart. Choose custom timeframes to analyze BMNDF price movements and trends.
BMNDF Company Profile
Discover essential business fundamentals and corporate details for Biomind Labs Inc. (BMNDF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jul 2021
Employees
5.00
Website
https://www.biomindlabs.comCEO
Alejandro Antalich
Description
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
BMNDF Financial Timeline
Browse a chronological timeline of Biomind Labs Inc. corporate events including earnings releases, dividend announcements, and stock splits.
BMNDF Stock Performance
Access detailed BMNDF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.